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understanding of the pathological mechanism of 
this disorder, a number of phenomena have not 
been fully elucidated.
One of the ongoing open questions is the lack 
of a correlation between the phenotype and gen‑
otype of patients with HAE.1,6,7 Also, despite 
a constantly low level and activity of C1 ‑INH, 
some patients may experience symptom ‑free pe‑
riods or suffer from angioedema.8 Another in‑
teresting aspect is related to the disease course, 
which is different among the individuals from 
the same family despite similar genetic chang‑
es in the SERPING1 gene.9 As indicated by previ‑
ous studies, neither the type of genetic changes 
INTROduCTION  Hereditary angioedema 
(HAE) due to C1 inhibitor (C1 ‑INH) deficiency 
(C1 ‑INH ‑HAE) is a rare autosomal dominant dis‑
ease caused by C1 ‑INH deficiency (type I, 85% of 
patients with low antigenic and functional plasma 
levels of C1 ‑INH) or C1 ‑INH dysfunction (type II, 
15% of patients with normal or elevated plasma 
levels of C1 ‑INH and low functional levels of C1‑
‑INH).1 C1 inhibitor is essential for numerous 
physiological processes, including complement 
and coagulation systems as well as fibrinolysis 
and the kinin system.1-5 The disease is caused by 
heterogeneous mutations within the C1 ‑INH gene 
(SERPING1).6,7 Despite considerable progress in 
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ABsTRACT
INTROduCTION Hereditary angioedema (HAE) is a rare autosomal dominant disease caused by genetic 
dysfunction of C1 inhibitor (C1 ‑INH) due to mutations in the SERPING1 gene. The disorder is mediated 
mainly by bradykinin. The clinical course of the disease is varied and not related to genetic changes.
OBjECTIvEs We aimed to evaluate redox homeostasis of peripheral blood mononuclear cells (PBMCs) 
in patients with HAE due to C1 ‑INH deficiency (C1 ‑INH ‑HAE) by measuring the levels of reactive oxygen 
species (ROS) of PBMCs as well as plasma advanced glycation end products (AGEs) and advanced 
oxidation protein products (AOPPs). We also aimed to assess the effect of bradykinin on ROS levels.
PATIENTs ANd mEThOds We enrolled 30 adults with C1 ‑INH ‑HAE and 15 healthy individuals. The levels 
of ROS were measured by flow cytometry, while the plasma levels of AGEs and AOPPs were determined 
spectrophotometrically by enzyme ‑linked immunosorbent assays.
REsuLTs Basal and hydrogen peroxide (H2O2)–induced ROS levels were higher in patients with HAE 
when compared with controls (P = 0.002 and P = 0.001, respectively), indicating abnormalities in redox 
homeostasis. Plasma AOPP and AGE levels were similar in both groups. Bradykinin reduced basal and 
H2O2 ‑induced ROS generation in PBMCs only in patients with HAE (P = 0.03).
CONCLusIONs The higher basal and H2O2 ‑induced ROS levels in patients with C1 ‑INH ‑HAE indicate re‑
dox imbalance. However, by reducing basal and H2O2 ‑induced ROS levels, bradykinin shows antioxidant 
action in this disorder.
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Moreover, we evaluated the effect of bradykinin 
on basal and H2O2 ‑induced levels of ROS in vitro.
PATIENTs ANd mEThOds The study included 
30 patients (21 women and 9 men) with C1 ‑INH‑
‑HAE types I and II, diagnosed and remaining un‑
der the care of the HAE Center in Krakow, Poland 
(TABLE 1). The diagnosis of C1 ‑INH ‑HAE was estab‑
lished on the basis of patient and family history, 
examination during angioedema attacks, as well 
as reduced serum C1 ‑INH antigen levels and C1‑
‑INH activity below 50% of the reference values 
according to international criteria.6 The exclusion 
criteria were the presence of concurrent diseas‑
es and medication use. Blood samples were ob‑
tained during remission (no attacks for at least 2 
weeks). Clinical and laboratory characteristics of 
the study group are presented in TABLE 1.
The severity of C1 ‑INH ‑HAE was evaluated us‑
ing a 3 ‑grade scale of symptom severity (0, as‑
ymptomatic; 1, mild [<6 attacks/year]; 2, mod‑
erate [6–12 attacks/year), and 3, severe [>12 at‑
tacks/year) (modified by Agostini et al).14
The biochemical diagnosis of C1 ‑INH ‑HAE was 
established during the remission of symptoms 
and was based on the measurement of serum 
C1 ‑INH and complement component C4 levels 
as well as functional activity of plasma C1 ‑INH. 
Serum C1 ‑INH and C4 levels were measured by 
nephelometry with specific C1 ‑INH antiserum 
(Siemens Healthcare Diagnostics GmbH, Mar‑
burg, Germany), and the functional level of C1‑
‑INH was determined using a functional chromo‑
genic assay, Berichrom C1 ‑INH (Siemens Health‑
care Diagnostics GmbH).
The control group included 15 healthy individ‑
uals (11 women and 4 men; mean age, 48 years; 
range, 30–61 years). All controls had a negative 
family history of HAE and normal serum levels of 
C1 ‑INH (median, 0.22 g/l [range, 0.21–0.29 g/l]; 
reference range, 0.21–0.39 g/l), functional activi‑
ty of C1 ‑INH (median, 96.6% [range, 74%–119%]; 
reference range, 70%–130%), and serum C4 lev‑
els (median, 0.21 g/l [range, 0.18–0.3 g/l]; refer‑
ence range, 0.1–0.4 g/l).
The study was approved by the Ethics Commit‑
tee of Jagiellonian University in Krakow (104/
B2014, 22 May 2014), and patients signed a writ‑
ten informed consent form. The study was carried 
out in accordance with the Declaration of Helsin‑
ki and its amendments.
measurement of intracellular reactive oxygen spe-
cies generation Anticoagulant ‑treated blood was 
collected in EDTA tubes and layered over a lym‑
phocyte separation medium (Ficol, PAN ‑Biotech 
GmbH, Aidenbach, Germany), enabling PBMC 
isolation by centrifugation in a density gradi‑
ent medium (400 g, 30 minutes, 20°C). The iso‑
lated cells were rinsed with phosphate ‑buffered 
saline (Gibco, Invitrogen, Paisley, United King‑
dom) supplemented with 1% fetal bovine serum 
(Gibco) (400 g, 6 minutes, 4°C), and then count‑
ed using the Bürker chamber.
nor complement parameters allow a prediction 
of the clinical course of the disease.2,7,9
It is generally accepted that bradykinin is 
the main mediator inducing an angioedema at‑
tack in patients with C1 ‑INH ‑HAE.2-5,10-12 Brady‑
kinin is a tissue hormone generated by the kinin 
system as an inflammatory product of the co‑
agulation system.1,2,3,10 -12 It acts via bradykinin 
B2 receptor (B2R) and is very quickly inactivated. 
However, its metabolites act via actively formed 
bradykinin B1 receptors (B1R). Bradykinin exerts 
several physiological effects. It increases the per‑
meability of capillaries, leading to local edema, 
warming, and erythema. Its vasodilating activi‑
ty results in the release of 3 potent mediators: 
tissue plasminogen activator, prostacyclin, and 
endothelium ‑derived vascular relaxing factor. 
Bradykinin ‑mediated angioedema seems to oc‑
cur in individuals with hereditary or acquired 
C1 ‑INH deficiency owing to an easy activation of 
the complement, plasma contact, and kinin sys‑
tem, as a result of uncontrolled overproduction 
of kallikrein and, in consequence, of bradykinin. 
There may be various direct reasons for the in‑
crease of serum bradykinin levels inducing an‑
gioedema in a given patient, which are often dif‑
ficult to establish.
Patients with C1 ‑INH ‑HAE report diverse 
nonspecific triggers inducing the attacks of ede‑
ma, such as trauma or injury, pressure, effort, 
stress, or infection.1-3,13 Bradykinin ‑mediated an‑
gioedema may be also caused by various meta‑
bolic products and environmental agents.8 These 
diversity of triggers in patients with C1 ‑INH‑
‑HAE suggests the presence of reactions based 
on a feedback phenomenon, allowing the human 
body to adapt to the changing internal or exter‑
nal environment independently from the stimu‑
lus, as well as to maintain homeostasis, in which 
appropriate redox balance may play an essen‑
tial role.
The aim of the study was to evaluate oxidative 
stress in patients with C1 ‑INH deficiency by mea‑
suring basal and hydrogen peroxide (H2O2)–in‑
duced levels of reactive oxygen species (ROS) in 
peripheral blood mononuclear cells (PBMCs) as 
well as by measuring the plasma concentrations 
of advanced glycation end products (AGEs) and 
advanced oxidation protein products (AOPPs). 
whAT’s NEw?
Hereditary angioedema due to C1 ‑inhibitor deficiency (C1 ‑INH ‑HAE) is a rare 
hereditary disease, in which the deficiency of C1 inhibitor disturbs the ho‑
meostasis of numerous systems, metabolism, and immunity. We examined 
the markers of redox imbalance (basal and hydrogen peroxide [H2O2]–induced 
levels of reactive oxygen species [ROS], plasma advanced glycation end 
products, and advanced oxidation protein products) in patients with C1 ‑INH‑
‑HAE types I and II. We also assessed the effect of exogenous bradykinin on 
ROS levels. Our results are groundbreaking in that they revealed a significant 
increase in basal and H2O2 ‑induced ROS levels as well as antioxidant action 
of exogenous bradykinin in patients with C1 ‑INH ‑HAE.
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25 mM; HEPES acid, 10 mM; pH adjusted to 7.4) 
to the final concentration of 100 µM. Bradyki‑
nin (Bachem, Bubendorf, Switzerland) was dis‑
solved in water as the stock solution and kept fro‑
zen at a temperature of –20°C until mixed with 
the loading buffer to the final concentration of 
100 pM. H2O2 (Farmina, Kraków, Poland) was 
diluted in the loading buffer to the final concen‑
tration of 1 mM.
The plasma concentrations of AGEs and AOPPs 
were measured spectrophotometrically using 
commercially available enzyme ‑linked immuno‑
sorbent assay kits (Bioassay Technology Labora‑
tory, Shanghai, China) and a microplate reader 
(Multiskan, Termo Fisher Scientific, Waltham, 
Massachusetts, United States). Each sample was 
analyzed in duplicate.
statistical analysis The Shapiro–Wilk test was 
used to assess the normality of variable distri‑
bution, and the Levene test was applied to as‑
sess the homogeneity of variance. Data were pre‑
sented as median and lower and upper quartiles 
(Q1; Q3). Box and whisker plots were generated 
with Statistics v13.0 (Statsoft Inc., Tulsa, Okla‑
homa, United States) and showed the median, in‑
terquartile range (IQR), and minimum and max‑
imum values. The Mann–Whitney test was used 
to compare patient and control groups as well as 
to compare bradykinin ‑treated and ‑untreated 
PBMCs. The significance level was set at a P val‑
ue of less than 0.05. The Spearman rank corre‑
lation test was used to identify correlations be‑
tween AOPP and AGE levels both in the study 
and control groups. Analyses were conducted us‑
ing the Statistica software package version 13.0 
(Statsoft Inc.).
REsuLTs Basal ROS levels, expressed as DCF flu‑
orescence intensity in relative fluorescence units 
(RFUs), were higher in PBMCs isolated from pa‑
tients with HAE than in those obtained from con‑
trols (median [Q1; Q3], 2967 RFUs [2634; 3800] 
vs 2147 RFUs [1690; 2786]; P = 0.002; FIGuRE 1). 
H2O2 ‑induced ROS levels were also higher in 
PBMCs obtained from HAE patients than in those 
from healthy controls (median [Q1; Q3], 6672 
RFUs [5 140; 10 494] vs 4352 RFUs [3390; 5531]; 
P = 0.001), indicating that patients with HAE 
have disturbances in redox homeostasis (FIGuRE 2).
The  median plasma levels of AOPPs and 
AGEs were similar in patient and control groups 
(P = 0.28 and P = 0.5, respectively; FIGuREs 3 and 4). 
Increased AOPP levels in patients with HAE were 
positively correlated with increased AGE values 
(r = 0.93, P <0.00001). A similar correlation was 
also observed in controls (r = 0.93, P <0.00001).
In our study, exogenous bradykinin was shown 
to act as an antioxidant by lowering basal and 
H2O2 ‑induced ROS levels in PBMCs. Exposure 
to bradykinin reduced basal ROS levels in pa‑
tients with HAE (median [Q1; Q3], 2967 RFUs 
[634; 3800] vs 2617 RFUs [2119; 3051]; P = 0.03; 
FIGuRE 5A), but not in controls (median [Q1; Q3], 
To detect ROS generation, flow cytometry 
with 2’,7’‑dichlorodihydrofluorescein diacetate 
(DCFH ‑DA) dye (Sigma ‑Aldrich, St. Louis, Mis‑
souri, United States) was used, according to Wang 
et al15 and Sarkar et al.16 DCFH ‑DA is a stable 
nonfluorescent and cell ‑permeable compound, 
which is converted within the cell to nonfluores‑
cent DCFH by intracellular esterases. The deester‑
ified product is oxidized by intracellular ROS to 
the highly fluorescent 2’7’‑dichlorofluorescein 
(DCF). The intensity of green fluorescence upon 
excitation at 488 nm is proportional to the in‑
tracellular level of ROS. For this assay, PBMCs 
isolated from blood were cultured in medium 
for 24 hours. Then, the cells were washed with 
Krebs–Ringer–Hepes (KRH) buffer, transferred 
into 2 tubes, and incubated with or without 100‑
‑pM bradykinin in KRH buffer for 10 minutes. 
After that, both samples were loaded with 100‑
‑µM DCFH ‑DA in KRH buffer. After incubation in 
5% CO2/95% air at 37°C for 45 minutes in dark, 
the cells were washed, divided into 2 aliquots, and 
suspended in KRH buffer. The free radical generator 
H2O2 (1 μM) was added extracellularly to one sam‑
ple for 10 minutes. Then, basal and H2O2 ‑induced 
ROS levels were measured in PBMCs. DCF fluores‑
cence was measured by flow cytometry (FACS Can‑
to II, Becton Dickinson, San Jose, California, Unit‑
ed States). Data were acquired and analyzed using 
the DIVA software (Becton Dickinson).
DCFH ‑DA was dissolved in dimethyl sulfoxide 
(Sigma ‑Aldrich) as the stock solution and kept 
frozen at a temperature of –20°C. For cell load‑
ing, DCFH ‑DA from stock solution was mixed 
with KRH loading buffer (NaCl, 116 mM; KCl, 
4 mM; MgCl2, 1 mM; CaCl2, 1.8 mM; glucose, 
TABLE 1 Clinical characteristics of patients (n = 30) with hereditary angioedema due 
to C1 ‑inhibitor deficiency (types I and II)
Parameter Value
Sex, n Female 21
Male 9
Family history, n Yes 15
No 15
HAE type, n I 24
II 6
Age, y 37.5 (26; 53)
C1 ‑INHa, g/l Type I 0.06 (0.04; 0.069)
Type II 0.425 (0.22; 0.683)
fC1 ‑INHb, % 22.3 (10.3; 26)
C4c, g/l 0.049 (0.034; 0.067)
Symptom score, 0–3 2 (1.25; 3)
Data are presented as median (Q1; O3) unless otherwise indicated.
a Reference range, 0.21–0.39 g/l
b Reference range, 70%–130%
c Reference range, 0.1–0.4 g/l
Abbreviations: C1 ‑INH, C1 inhibitor; C4, complement component 4; fC1 ‑INH, functional 
activity of C1 inhibitor; HAE, hereditary angioedema
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confirms that these patients have impaired redox 
balance with a significant prevalence of free rad‑
icals. Moreover, we found that the use of H2O2 as 
a nonspecific stimulus applied to PBMCs signifi‑
cantly increased ROS levels in patients with C1‑
‑INH ‑HAE when compared with controls. This in‑
dicates an increased tendency of PBMCs to pro‑
duce free radicals when subjected to nonspecif‑
ic stimuli and confirm disturbances in the redox 
homeostasis in this patient group.
In our study, we used DCFH ‑DA to monitor 
changes in the redox status in PBMCs in response 
to the activation with an oxidative stimulus, 
2147 RFUs [1690; 2786] vs 2022 RFUs [1347; 
2392]; P = 0.31; FIGuRE 5B). Moreover, exposure 
to bradykinin decreased also H2O2 ‑induced 
ROS levels in patients with HAE (median, 6672 
RFUs [IQR, 5140–10 494] vs 5554 RFUs [IQR, 
3854–6989]; P = 0.046; FIGuRE 6A), but not in con‑
trols (median, 4352 RFUs [IQR, 3390–5531] vs 
4126 RFUs [IQR, 2726–4486]; P = 0.23; FIGuRE 6B).
dIsCussION To our knowledge, our study is 
the first to show that patients with type I or 
II C1 ‑INH ‑HAE have increased levels of basal 
ROS in PBMCs as compared with controls, which 
FIGuRE 1 Basal 
reactive oxygen species 
(ROS) levels in peripheral 
blood mononuclear cells 
from patients with 
hereditary angioedema 
(HAE) and healthy 
controls
a  P <0.05; HAE vs 
control (Mann–Whitney 
test) 
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FIGuRE 2 H2O2 ‑induced 
reactive oxygen species 
(ROS) levels in peripheral 
blood mononuclear cells 
from patients with 
hereditary angioedema 
(HAE) and healthy 
controls
a  P <0.05; HAE vs 
control (Mann–Whitney 
test)
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the blood, as additional biomarkers of oxidative 
stress, which tends to be elevated in patients with 
C1 ‑INH ‑HAE. However, the difference in AOPP 
and AGE levels between patients and controls 
was not significant. We observed that AGE levels 
higher than 1000 ng/l were present only in plas‑
ma samples from patients with C1 ‑INH ‑HAE but 
not in healthy controls. Del Giacco et al18 studied 
patients with C1 ‑INH ‑HAE as well as those with 
HAE with mutations in the F12 gene (FXII ‑HAE). 
They reported that AGE levels were elevated only 
because DCFH can be oxidized by various ROS. 
Thus, an increase of intracellular DCF fluorescence 
reflects the overall oxidative stress index in cells. 
Oxidative stress occurs in cells when the gener‑
ation of ROS overwhelms the cells’ natural an‑
tioxidant defenses. DCFH ‑DA may be used as 
a redox indicator probe that responds to chang‑
es in intracellular iron signaling or peroxynitrite 
formation.17
Moreover, in our study, we used AOPPs and 
AGEs, modified by interactions with ROS in 
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FIGuRE 3 Plasma 
levels of advanced 
oxidation protein products 
(AOPPs) in patients with 
hereditary angioedema 
(HAE) and healthy 
controls
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FIGuRE 4 Plasma 
levels of advanced 
glycation end products 
(AGEs) in patients with 
hereditary angioedema 
(HAE) and healthy 
controls
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inadequate effectiveness of antioxidant defense 
mechanisms. This imbalance can worsen inflam‑
mation and injury conditions by enhancing the re‑
lease of proinflammatory cytokines and altering 
enzymatic function,10,19 by activating the com‑
plement20-22 and kinin systems as well as kinin 
receptors,23-27 by endothelial cell activation and 
dysfunction,25,28-31 as well as by affecting gene ex‑
pression.32 C1 ‑inhibitor deficiency can aggravate 
these effects, especially by impaired redox homeo‑
stasis and increased oxidative stress in patients 
with C1 ‑INH ‑HAE, as shown by Del Giacco et al18 
and also by our team.
in the C1 ‑INH ‑HAE group, as compared with con‑
trols, but not in the FXII ‑HAE group. In contrast, 
C1 ‑INH deficiency did not seem to affect AOPP 
levels, as both C1 ‑INH ‑HAE and FXII ‑HAE groups 
showed elevated AOPP levels, as compared with 
controls.18 Therefore, further research on a larg‑
er group of patients and using the same measure‑
ment methods is needed to verify the values of 
these promising and important parameters for 
the assessment of oxidative stress involved in 
the pathophysiology of HAE.
Oxidative stress results from an imbalance be‑
tween endogenous production of free ROS and 
FIGuRE 5 Effect of 
bradykinin on basal 
reactive oxygen species 
(ROS) levels in peripheral 
blood mononuclear cells 
(PBMCs) from patients 
with hereditary 
angioedema (A) and 
healthy controls (B) 
a  P <0.05; bradykinin‑
‑treated vs intact PBMCs 
(Mann–Whitney test)
Median
Q1–Q3
Min–Max
Median
Q1–Q3
Min–Max
0
1000
2000
3000
4000
5000
6000
7000
8000
Intact 
1000
2000
3000
4000
5000
6000
7000
8000
(+) Bradykinin
Intact (+) Bradykinin
a
RO
S,
 R
FU
s
RO
S,
 R
FU
s
A
B
ORIGINAL ARTICLE Bradykinin and oxidative stress in hereditary angioedema 85
C1 ‑INH ‑HAE. This seems to corroborate the find‑
ings reported so far in animal models33,34 as well 
as experimental studies on degenerative disease 
and cell aging processes in humans.24,25,35-39
Our results concerning oxidative stress in C1‑
‑INH ‑HAE as well as the effect of bradykinin on 
oxidative stress in PBMCs in this patient pop‑
ulation were presented as preliminary findings 
during 2018 Bradykinin Symposium in Ber‑
lin.40 They are generally consistent with the re‑
cent study by Del Giacco et al,18 who indicated 
Our results concerning the effect of exogenous 
bradykinin on basal and H2O2 ‑induced ROS levels 
in PBMCs in patients with C1 ‑INH ‑HAE showed 
that bradykinin exerted a significant antioxidant 
effect in this group of patients. The lack of antiox‑
idant bradykinin action in healthy controls may 
be associated with normal C1 ‑INH levels or may 
indicate that this effect manifests only in the case 
of increased oxidative stress.
To our knowledge, this is the first study con‑
firming the antioxidant action of bradykinin in 
FIGuRE 6 Effect of 
bradykinin on H2O2‑
‑induced reactive oxygen 
species (ROS) levels in 
peripheral blood 
mononuclear cells 
(PBMCs) from patients 
with hereditary 
angioedema (A) and 
healthy controls (B)
a  P <0.05 bradykinin‑
‑treated vs intact PBMCs 
(Mann –Whitney test)
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by hypoxia–reperfusion injury, the expression 
of B2R is significantly increased.
44,45 This recep‑
tor may play a neuroprotective role in hypoxia–
reoxygenation injury related to the pyroptosis 
pathway. It could be hypothesized that the same 
upregulation of the B2R expression occurs under 
the condition of oxidative stress documented in 
patients with C1 ‑INH ‑HAE. However, further re‑
search is needed to fully explain the role of B1R 
and B2R as well as the endothelium and oxidative 
stress in the pathophysiology of C1 ‑INH ‑HAE.
Although some previous studies have indicated 
the antioxidant property of bradykinin in animal 
models, the involvement of bradykinin in intra‑
cellular redox processes has not been fully eluci‑
dated. Bradykinin was found to protect endothe‑
lial cells against oxidative stress or enhanced ROS 
generation.29,31 It seems that the effect of brady‑
kinin on the intracellular redox state depends on 
the type of the receptor with which the kinins or 
their derivatives interact.1,18,34
A study using bradykinin receptor–null mice 
indicated that nonselective stimulation of B1R 
and B2R is likely to suppress oxidative stress and 
diabetic nephropathy,23 while other studies sug‑
gested that the selective activation of B2R
25 and 
inhibition of B1R could be beneficial.
27,46 Data 
from studies on the vascular system of diabet‑
ic rats showed that B1R enhances superoxide an‑
ion radical formation by activating NADPH oxi‑
dase.18,27,46 Moreover, it has been shown that oxi‑
dative stress caused by elevated superoxide anion 
production induces expression of the kinin B1R in 
the liver and brain of diabetic rats.46-48
In light of recent findings, the cooperation be‑
tween G protein–coupled receptors makes the sig‑
nal transduction pathways of active peptides even 
more complex.18,49 Thus, oligomerization of bra‑
dykinin receptors and other receptors may mod‑
ulate physiological processes and partially ac‑
count for the discrepancies between bradykinin 
effects reported in different studies. Therefore, 
the expression and activation of B1R and B2R in 
patients with C1 ‑INH ‑HAE should be investigat‑
ed in further studies.
Bradykinin is known to induce nitric oxide syn‑
thase and release, which may lead to an increased 
production of peroxynitrite radicals, especial‑
ly when antioxidant systems are not efficient. 
At the same time, bradykinin was proved to stim‑
ulate the activity of the antioxidant enzymes su‑
peroxide dismutase and catalase in endothelial 
cells.18,49 This recent evidence corroborates a pre‑
vious study reporting an increase in superoxide 
dismutase, catalase, and glutathione peroxidase 
activity in hyperglycemic rats.47,48 On the basis 
of these findings as well as our data, a hypothe‑
sis may be proposed that one of the various bra‑
dykinin effects is to maintain the redox balance.
One of the limitations of our study is the use 
of a single measurement of bradykinin levels. 
The use of different concentrations of bradyki‑
nin in PBMC samples would be valuable, but it 
was not possible owing to the limited amount of 
the role of oxidative stress in the pathophysiol‑
ogy of C1 ‑INH ‑HAE.
We focused on the  effect of bradykinin on 
PBMCs, as these cells can be separated from 
an easily accessible specimen; thus, we chose flow 
cytometry analysis with DCFH ‑DA as a fluores‑
cent probe. Flow cytometry is one of the most 
powerful tools for single ‑cell analysis of the im‑
mune system used for many years to evaluate ox‑
idative burst in numerous conditions, such as au‑
toimmune neutropenia and asymptomatic HIV in‑
fection.41 DCFH ‑DA has been also widely used for 
the detection of ROS and reactive nitrogen spe‑
cies, especially in mononuclear leukocytes (while 
other fluorescent probes are used only for poly‑
morphonuclear leukocytes). This probe detects 
more reactive species (HO·, ONOO–, ROO·, NO2·, 
H2O2) than other probes. Isolation of PBMCs from 
whole blood and stabilization in the medium al‑
lowed us to avoid some factors interfering with 
ROS determination.42
Although the major effects of bradykinin are ex‑
erted on the endothelium, previous data showed 
the expression of B2R and B1R on the surface of 
PBMCs, indicating other target cells for brady‑
kinin action.43 Although B1R is a potent activa‑
tor of inducible nitric oxide and NADPH oxidase, 
potentially leading to oxidative stress, the role of 
B2R in this process is unclear. Based on a recent 
study on the role of bradykinin in neuroprotec‑
tion, the molecular mechanisms of bradykinin’s 
action involve downregulation of the expression 
of caspase 1, interleukins 1β and 18, and cleaved 
gasdermin D (a key executioner of pyroptosis).44 
Moreover, human tissue kallikrein gene deliv‑
ery was found to protect against cerebral isch‑
emia–reperfusion injury through B2R activation, 
and the proposed novel signaling mechanisms 
involved the activation of Homer1b/c ‑ERK1/2 
and Homer1b/c ‑PI3K ‑Akt signaling pathways.45 
Based on our results, the next step in further re‑
search on the antioxidant activity of bradyki‑
nin in the model of PBMCs in patients with C1‑
‑INH ‑HAE should be a transcriptomics analysis 
of the signaling pathways.
Patients with C1 ‑INH ‑HAE have significant‑
ly elevated intracellular ROS levels in PBMCs 
compared with healthy individuals. In the case 
of an adverse process such as oxidative stress, 
when redox balance is disturbed, different an‑
tioxidants may decrease ROS levels to some ex‑
tent. Nevertheless, a number of free radicals in 
the cells of healthy controls is needed as signal‑
ing molecules, and ROS are generated continu‑
ously in physiological processes. Therefore, this 
so called “oxidative eustress” is not affected by an‑
tioxidants. It is known that cytokines produced 
by macrophages and mast cells, occurring in var‑
ious diseases including HAE, promote overex‑
pression of NADPH oxidase, which is the main 
source of excess ROS (apart from nitric oxide syn‑
thase and xanthine oxidase) in ischemia–reper‑
fusion injury.18,23,34 Recently, it has been report‑
ed that in the state of oxidative stress mediated 
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PBMC specimen, as only a limited blood volume 
could be drawn from patients according to ethi‑
cal standards. Thus, the concentration of brady‑
kinin (100 pM) was chosen based on data on se‑
rum bradykinin concentrations during acute at‑
tacks of angioedema, provided in reliable litera‑
ture sources.50 Our results should be confirmed 
in a larger study, together with the assessment 
of a dose dependency of bradykinin’s antioxidant 
action in C1 ‑INH ‑HAE.34
In our study, exposure to bradykinin decreased 
also H2O2 ‑induced ROS levels in patients with C1‑
‑INH ‑HAE. It seems that in these patients, oxida‑
tive stress disturbing redox balance may induce 
an increase in bradykinin levels in a feedback re‑
action in order to recover impaired redox homeo‑
stasis. Future research should focus on elucidat‑
ing the role of kinins and kinin receptors as well 
as the endothelium in the pathomechanism of 
bradykinin ‑mediated angioedema. A full expla‑
nation of the role of oxidative stress and antiox‑
idant action of bradykinin might have important 
implications for the prevention and treatment of 
C1 ‑INH ‑HAE.18,35,40
In conclusion, our study is the first to reveal 
a significant increase in basal and H2O2 ‑induced 
ROS levels in patients with C1 ‑INH ‑HAE as well 
as antioxidant action of exogenous bradykinin. 
It seems also that in patients with C1 ‑INH ‑HAE, 
elevated oxidative stress may induce an increase 
of bradykinin levels as a natural antioxidant as 
a result of a feedback reaction provoking an an‑
gioedema attack. Further studies on the role of 
oxidative stress and antioxidant action of bra‑
dykinin might have important implications for 
the prevention and treatment of C1 ‑INH ‑HAE.
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